AMF TT Cones

K234011 · Lima Corporate S.P.A. · JWH · Jan 18, 2024 · Orthopedic

Device Facts

• Record ID: K234011
• Device Name: AMF TT Cones
• Applicant: Lima Corporate S.P.A.
• Product Code: JWH · Orthopedic
• Decision Date: Jan 18, 2024
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 888.3560
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

AMF TT Cones are intended for use in skeletally mature patients with bone defect or poor bone quality (osteoporotic bone) or in case of sclerotic bone that requires supplemental metaphyseal fixation in the clinical judgment of the surgeon. Tibial and femoral cones are intended for uncemented fixation to the bone and are fixed to the femoral and tibial implants using bone cement.

Device Story

AMF TT Cones are one-piece, conically shaped, cannulated accessory components for total knee arthroplasty; manufactured from Ti6Al4V alloy. Used as supplemental metaphyseal fixation for femoral and tibial implants in patients with bone defects or poor bone quality. Cones are fixed to bone via uncemented fixation and to implants using bone cement. Device is used in clinical surgical settings by orthopedic surgeons. This submission specifically establishes compatibility between existing AMF Revision TT Cones and the EMPOWR Revision Knee system. Output is a structural implant component providing mechanical support to the knee prosthesis; aids surgeon in achieving stable fixation in compromised bone environments.

Clinical Evidence

No clinical data. Substantial equivalence demonstrated via non-clinical mechanical testing and design control analysis.

Technological Characteristics

Material: Ti6Al4V alloy. Form factor: One-piece, conically shaped, cannulated. Fixation: Uncemented to bone, cemented to femoral/tibial implants. Sterilization: Not specified. Connectivity: N/A. Software: None.

Indications for Use

Indicated for skeletally mature patients with bone defects, poor bone quality (osteoporotic), or sclerotic bone requiring supplemental metaphyseal fixation during total knee arthroplasty.

Regulatory Classification

Identification

A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).

Predicate Devices

• AMF Revision TT Cones (K200653)

Reference Devices

• EMPOWR Revision Knee (K230169)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. Underneath the square are the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.

January 18, 2024

LimaCorporate S.p.A % Newman Kenneth Senior Regulatory Affairs Specialist Lima USA Inc 2001 NE Green Oaks Blvd. Ste.100 Arlington, Texas 76006

Re: K234011

Trade/Device Name: AMF TT Cones Regulation Number: 21 CFR 888.3560 Regulation Name: Knee Joint Patellofemorotibial Polymer Semi-Constrained Cemented Prosthesis Regulatory Class: Class II Product Code: JWH, MBH Dated: December 19, 2023 Received: December 19, 2023

Dear Newman Kenneth:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

{2}------------------------------------------------

Sincerely,

# Lixin Liu -S

Lixin Liu, Ph.D. Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

### Indications for Use

Expiration
See PRA.

Submission Number (if known)

K234011

Device Name

AMF TT Cones

#### Indications for Use (Describe)

AMF TT Cones are intended for use in skeletally mature patients with bone defect or poor bone quality (osteoporotic bone) or in case of sclerotic bone that requires supplemental metaphyseal fixation in the clinical judgment of the surgeon. Tibial and femoral cones are intended for uncemented fixation to the bone and are fixed to the femoral and tibial implants using bone cement.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

## K234011 Page 1 of 2

### Summary of Safety and Effectiveness

Date: December 19, 2023

Manufacturer: Limacorporate S.p.A. Via Nazionale, 52 33038 – Villanova di San Daniele Udine - Italy

U.S. Contact Person: Kenneth Newman [e-mail] Lima USA Inc. 2001 NE Green Oaks Blvd. Ste.100 Arlington, Texas 76006, USA www.limacorporate.com Cell Phone: [phone]

| Product | Common<br>Name | Product<br>Code | Regulation and Classification Name |
|-----------------|----------------------|-----------------|-------------------------------------------------------------------------------------------------------------------------|
| AMF TT<br>Cones | Total knee<br>system | JWH | Knee joint Patellofemorotibial<br>Polymer/Metal/Polymer Semi-<br>Constrained Cemented Prosthesis per 21<br>CFR 888.3560 |
| | | MBH | Knee joint Patellofemorotibial<br>metal/polymer porous-coated<br>uncemented prosthesis per 21 CFR<br>888.3565 |

#### Description

The AMF TT Cones are intended to be used as an optional accessory component in total knee arthroplasty. The AMF TT Cones are one-piece devices, made from Ti6A14V alloy, conically shaped with cannulation all the way through the cone.

With this 510(k) submission, the compatibility of the AMF Revision TT Cones (K200653) with the EMPOWR Revision Knee (K230169) manufactured by Encore Medical, L.P. is introduced.

#### Indications for use

AMF TT Cones are intended for use in skeletally mature patients with bone defect or poor bone quality (osteoporotic bone) or in case of sclerotic bone that requires supplemental metaphyseal fixation in the clinical judgment of the surgeon. Tibial and femoral cones are intended for uncemented fixation to the bone and are fixed to the femoral and tibial implants using bone cement.

#### Predicate Devices

| Device name | Cleared via | Company |
|-----------------------|-------------|----------------------|
| AMF Revision TT Cones | K200653 | LimaCorporate S.p.A. |

{5}------------------------------------------------

#### Summary of technology comparison

The intended use, principles of operation, design, materials, sterility and methods of fixation of AMF TT Cones are substantially equivalent to the ones of the predicate device. Design Control Activities have been successfully completed.

#### Non-clinical testing

The new compatibility introduced with this 510(k) does not introduce a worst case for mechanical testing. Test results of mechanical testing submitted in K200653 are applicable. Additional testing to demonstrate substantial equivalence to predicate devices is thus not required.

#### Clinical testing

Clinical testing was not necessary to demonstrate substantial equivalence of the new AMF TT Cones to the predicate device.

#### Conclusion

Based upon a comparison of intended use, materials, summary of technological characteristics, and preclinical testing, the AMF TT Cones are substantially equivalent to the predicate device identified in this premarket notification.